Sugi Predict

Sugi Predict / Compounds / SCHEMBL626223

SCHEMBL626223

SCHEMBL626223

CCCCCCCCCCCCCCCCCC(=O)CC(C[N+](C)(C)C)C(=O)CCCCCCCCCCCCCCCCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 4/20 0.47
▸ MAPT P10636 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ GMNN O75496 3/20 0.47
▸ LMNA P02545 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ NPSR1 Q6W5P4 3/20 0.47
▸ TP53 P04637 3/20 0.47
▸ TSHR P16473 3/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ HSP90AA1 P07900 2/20 0.47
▸ BLM P54132 2/20 0.47
▸ NR1H4 Q96RI1 2/20 0.47
▸ CYP2C9 P11712 2/20 0.47
▸ HIF1A Q16665 2/20 0.47
▸ CES2 O00748 1/20 0.46
▸ SLC25A20 O43772 3/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ GLA P06280 1/20 0.46
▸ PMP22 Q01453 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL625634 1.00 MAPK1 (0.47) MAPK1MAPTMEN1GMNNLMNA
SCHEMBL725613 1.00 MAPK1 (0.47) MAPK1MAPTMEN1GMNNLMNA
Hydrochloric Acid SCHEMBL17241611 0.98 MAPK1 (0.48) MAPK1MAPTMEN1GMNNLMNA
Hydrochloric Acid SCHEMBL1773167 0.98 MAPK1 (0.48) MAPK1MAPTMEN1GMNNLMNA
SCHEMBL29077348 0.91 SLC6A5 (0.52) MAPTMEN1GMNNLMNAKMT2A
SCHEMBL533830 0.91 SLC6A5 (0.52) MAPTMEN1GMNNLMNAKMT2A
SCHEMBL533829 0.91 SLC6A5 (0.52) MAPTMEN1GMNNLMNAKMT2A
Hydrochloric Acid SCHEMBL20258167 0.90 SLC6A5 (0.51) MAPTMEN1GMNNLMNAKMT2A
Hydrochloric Acid SCHEMBL1773161 0.90 SLC6A5 (0.51) MAPTMEN1GMNNLMNAKMT2A
Hydrochloric Acid SCHEMBL28566602 0.90 SLC6A5 (0.51) MAPTMEN1GMNNLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113616618-B Capecitabine polymer-lipid hybrid nanoparticles utilizing micro-mixing and capecitabine amphiphilic properties 杭州景杰生物科技股份有限公司 2022-11-08 — — CN claimed
US-20220288285-A1 CATIONIC NANODRUG, PREPARATION METHOD THEREFOR, AND DRUG-LOADED IMPLANTABLE MEDICAL DEVICE SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD. (CN) 2022-09-15 — — US claimed
EP-4026536-A1 CATIONIC NANODRUG, PREPARATION METHOD THEREFOR, AND DRUG-LOADED IMPLANTABLE MEDICAL DEVICE Shanghai MicroPort Medical (Group) Co., Ltd. (CN) 2022-07-13 — — EP claimed
US-20220211882-A1 METHOD AND DEVICE FOR PRODUCING OPTIMIZED LIPID-BASED MICRO/NANO-BUBBLES TRUST BIO SONIS INC (TW) 2022-07-07 — — US claimed
US-20220175955-A1 PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE DANMARKS TEKNISKE UNIVERSITET (DK) 2022-06-09 — — US claimed
US-20210213010-A1 TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS DANMARKS TEKNISKE UNIVERSITET (DK) 2021-07-15 — — US claimed
EP-3827002-A1 TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS Torque Therapeutics, Inc. (US) 2021-06-02 — — EP claimed
CN-112703199-A Displaying peptides on antigen presenting cells using lipid carriers 转矩医疗股份有限公司 2021-04-23 — — CN claimed
US-20200297874-A1 METHOD AND DEVICE FOR PRODUCING OPTIMIZED LIPID-BASED MICRO/NANO-BUBBLES TRUST BIO SONICS INC (TW) 2020-09-24 — — US claimed
US-20200163880-A1 CATIONIC LIPOSOMES DANMARKS TEKNISKE UNIVERSITET (DK) 2020-05-28 — — US claimed
CN-103394102-A Lipid micro/nano bubble, and optimized preparation method and preparation device thereof BOXIN BIOLOG TECHNOLOGY CO LTD 2013-11-20 — — CN claimed
WO-2013135800-A1 CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD BIONEER A/S (DK) 2013-09-19 — — WO claimed
EP-2638896-A1 Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood Bioneer A/S (DK) 2013-09-18 — — EP claimed
EP-2167124-B1 THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT STATENS SERUMINSTITUT (DK) 2012-08-01 — — EP claimed
US-20110287087-A1 MODIFIED CATIONIC LIPOSOME ADJUVANS STATENS SERUM INSTITUT (DK) 2011-11-24 — — US claimed
WO-2011098578-A2 LIPOSOME SYSTEM FOR OCULAR ADMINISTRATION BIONEER A/S (DK) 2011-08-18 — — WO claimed
EP-2355798-A1 MODIFIED CATIONIC LIPOSOME ADJUVANS Statens Serum Institut (DK) 2011-08-17 — — EP claimed
WO-2010054654-A1 MODIFIED CATIONIC LIPOSOME ADJUVANS STATENS SERUM INSTITUT (DK) 2010-05-20 — — WO claimed
US-20070014841-A1 Pharmaceutical compositions ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) 2007-01-18 — — US claimed
US-20020102297-A1 Macromolecule-lipid complexes and methods for making and using THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-08-01 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210213010-A1 TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS TLR7, TLR9, TLR8 MAPK1 1304/4885MAPT 4462/4885MEN1 2845/4885
US-20200163880-A1 CATIONIC LIPOSOMES CD14, LIPA, CETP MAPK1 3981/4885MAPT 2651/4885MEN1 2890/4885
US-20220175955-A1 PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE CD74, MICA, TAP1 MAPK1 3814/4885MAPT 3005/4885MEN1 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.